The primary aim of this study is to attempt to provide a means of restoring evangelical preaching in Xhosa churches. I will attempt to answer the question, How can the evangelical preaching be restored in Xhosa churches in the Western Cape? From personal observation, it is clear that in contemporary Xhosa evangelicalism, preaching is totally misunderstood. To put more bluntly, there are no clear criteria from biblical theology for preaching in Xhosa churches. Indeed so much is happening in the name of preaching that offers no substance whatsoever. In the first two chapter’s of this study, the focus is on the problem that the Xhosa church is experiencing and how preaching is understood and practiced in this community. Chapter three examines the causes of the problem and how to deal with those causes. On a practical note, it is shown that sermon analyses are inevitable for further consideration of the problem. Moreover, the chapter examines various attempts that have been made in response to the problem. In Chapter four, an investigation of the views of biblical theology on the subject of preaching is carried out. The chapter dwells into what the Bible offers on the subject of preaching and this is meant to serve as a foundation for the restoration of evangelical preaching in Xhosa churches. In the light of Chapter four, Chapter five argues for expository preaching as a possible means of responding to the crisis which the Xhosa church is experiencing. At the same time chapter five seek to state the case for expository preaching. Finally, Chapter Six provides the most effective material for Xhosa preachers in the process of exploring and constructing expository sermons. / Dissertation (MA(Theol))--University of Pretoria, 2009. / Practical Theology / unrestricted

Stabilization of poorly graded sand in full-scale applications is challenging. This thesis evaluated cement-stabilized sand and had two objectives: (1) evaluation of stabilized material using the PM device to quantify engineering properties for future comparison to alterative materials and to investigate the effectiveness of the device with sand and (2) investigation of the merits of alternative application of cement to sand to benchmark against other topically applied materials. The PM device was successfully used to recommend 10% cement for field studies with one sand, successfully allowed data collection in laboratory and field applications, and its potential in sand seems promising though more overarching conclusions on characterization of sand using the PM device are withheld for subsequent efforts. Topical application methods developed in this thesis were able to percolate cement into sand and produce an average estimated unconfined compressive strength of 245 psi measured on cores that were 2.5 inches thick.

No description available.

No description available.

No description available.

No description available.

No / Pomiferin is a unique, prenylated isoflavonoid that can be isolated and purified from the fruits of Maclura pomifera (Osage Orange). The molecule typically is isolated with a small amount of a molecule called Osajin which is structurally similar to Pomiferin but lacks an aromatic hydroxyl group. As a consequence, Osajin has been shown to be a less effective antioxidant than Pomiferin. In vitro studies on Normal Human Dermal Fibroblasts demonstrate that Pomiferin is a potent extracellular matrix protein stimulant, showing increases in collagen, elastin and fibrillin expression comparable or superior to equivalent concentrations of retinol. Ex vivo hair follicle assays demonstrate comparable effects on expression of collagen and elastin at Pomiferin concentrations in the range of 0.05–5 ppm. Taken together, the results from the two assays conducted on different models indicate that Pomiferin may be a very interesting ingredient for topical skin and scalp treatments where modulation of the expression of extracellular matrix proteins is important.

No / Larval biotherapy is a debridement tool used in wound management. The mechanism of action involves degradation of eschar by serine proteases including chymotrypsin within the alimentary fluids of first instar Lucilia sericata. With the rationale of obviating some limitations of biotherapy, including cost, complexity of use, and patient reticence, the present study describes a mobile hydrogel formulation containing freeze-dried recombinant L. sericata chymotrypsin designed for topical application. Neither freeze-drying nor formulation into the hydrogel significantly attenuated the measured activity of released enzyme compared to fresh-frozen enzyme in aqueous solution. Gel electrophoresis confirmed qualitatively that the chymotrypsin/hydrogel formulation both with and without supplementary urea at 10% w/v degraded human chronic wound eschar ex vivo. Mindful that the hallmark of intractability of chronic wounds is aberrant biochemistry, the pH activity profile for the enzyme/hydrogel formulation was compared with exudate pH in chronic wounds of mixed aetiology in a cohort of 48 hospital in-patients. Five patients' wounds were acidic, however, the remainder were predominantly alkaline and coincided with the pH optimum for the insect enzyme. Thus, a recombinant L. sericata chymotrypsin and hydrogel formulation could represent a pragmatic alternative to larval therapy for the management of chronic wounds.

Background: Evidence-based treatment algorithms, successfully established for asthma, are missing for atopic eczema (AE). Objectives: To investigate whether treatment according to an evidence-based algorithm is an effective and applicable concept for the management of AE. Methods: Based on a systematic literature review, we developed an evidence-based severity-score-oriented treatment algorithm for AE and compared its effectiveness to that of an individualised symptom-oriented treatment (individual therapy) in a randomised controlled trial. Sixty-three participants were randomised to algorithm (n = 32) or individual therapy (n = 31) and treated accordingly for 12 months. Study end points included difference between baseline SCORAD and mean SCORAD under treatment (primary end point), quality of life and treatment utilisation. Analysis was by intention to treat (registration: ClinicalTrials.gov:NCT00148746). Results: No statistically significant differences in clinical or subjective response were observed between groups. Treatment following the algorithm and individual treatment both effectively controlled AE. Mean SCORAD reductions were 47% (95% confidence interval, CI = 38–55; algorithm) and 42% (95% CI = 29–54; individual). Clinical response was paralleled by improved quality of life in both groups. Physicians adhered to the algorithm option in 93% of their treatment decisions. Conclusion: Treatment following an evidence-based algorithm is an effective and applicable concept for the management of AE but does not show clear advantages compared to individualised treatment in a dermatological setting. / Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.

Background: Evidence-based treatment algorithms, successfully established for asthma, are missing for atopic eczema (AE). Objectives: To investigate whether treatment according to an evidence-based algorithm is an effective and applicable concept for the management of AE. Methods: Based on a systematic literature review, we developed an evidence-based severity-score-oriented treatment algorithm for AE and compared its effectiveness to that of an individualised symptom-oriented treatment (individual therapy) in a randomised controlled trial. Sixty-three participants were randomised to algorithm (n = 32) or individual therapy (n = 31) and treated accordingly for 12 months. Study end points included difference between baseline SCORAD and mean SCORAD under treatment (primary end point), quality of life and treatment utilisation. Analysis was by intention to treat (registration: ClinicalTrials.gov:NCT00148746). Results: No statistically significant differences in clinical or subjective response were observed between groups. Treatment following the algorithm and individual treatment both effectively controlled AE. Mean SCORAD reductions were 47% (95% confidence interval, CI = 38–55; algorithm) and 42% (95% CI = 29–54; individual). Clinical response was paralleled by improved quality of life in both groups. Physicians adhered to the algorithm option in 93% of their treatment decisions. Conclusion: Treatment following an evidence-based algorithm is an effective and applicable concept for the management of AE but does not show clear advantages compared to individualised treatment in a dermatological setting. / Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.